← Return to Starting Bendamustine and Rituxin for Follicular Lymphoma

Discussion

Starting Bendamustine and Rituxin for Follicular Lymphoma

Blood Cancers & Disorders | Last Active: Apr 24, 2024 | Replies (14)
Comment receiving replies
@jam5

Wanting to know information concerning treatment with Brukinsa(zanabrutinib) versus Bendamustine and Rituxan for CLL What are the advantages or side effects in comparison ?
I believe Brukinsa has just been approved by the FDA.

Jump to this post

Replies to "Wanting to know information concerning treatment with Brukinsa(zanabrutinib) versus Bendamustine and Rituxan for CLL What are..."
Colleen Young, Connect Director | @colleenyoung | Jan 22, 2023

@jam5, you are watching new treatment developments for CLL very closely. 🙂 You're right that zanubrutinib (Brukinsa) was approved for use in patients with CLL and SLL just a few days ago (Jan. 19, 2023).

- FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma

Here's a study comparing zanubrutinib versus bendamustine and rituximab that shows promise:
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial | Lancet Oncology 2022 https://pubmed.ncbi.nlm.nih.gov/35810754/

EXCERPT:
"Interpretation: Zanubrutinib significantly improved progression-free survival versus bendamustine-rituximab, with an acceptable safety profile consistent with previous studies. These data support zanubrutinib as a potential new treatment option for untreated CLL and SLL."

VIEW AND REPLY